Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$68.44 USD

68.44
593,312

+1.07 (1.59%)

Updated Sep 18, 2025 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cardinal Health (CAH) Unveils the First Surgical Incise Drape

by Zacks Equity Research

Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.

Zacks Equity Research

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Zacks Equity Research

Align Technology (ALGN) Debuts Latest Feature for ClinCheck

by Zacks Equity Research

Align Technology's (ALGN) CBCT integration feature for ClinCheck will enable doctors to treat a broader range of cases with the Invisalign clear aligners.

Zacks Equity Research

Henry Schein (HSIC) Up 2.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

Zacks Equity Research

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Zacks Equity Research

Is Henry Schein (HSIC) a Suitable Pick for Value Investors?

by Zacks Equity Research

Is Henry Schein (HSIC) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Here's Why You Should Hold on to DaVita (DVA) Stock Now

by Zacks Equity Research

DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Hold on to Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.

Zacks Equity Research

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Zacks Equity Research

PerkinElmer's (PKI) Latest Launch to Boost Food Analysis Suite

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.

Zacks Equity Research

Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Zacks Equity Research

Boston Scientific (BSX) Hurt by Price and Volume Issues

by Zacks Equity Research

The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.

Zacks Equity Research

DexCom (DXCM) to Boost Diabetes Management With New Approval

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.

Zacks Equity Research

Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock For Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

Zacks Equity Research

Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales

by Zacks Equity Research

Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Baxter (BAX) to Enhance Its Portfolio With Latest Partnership

by Zacks Equity Research

Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.

Zacks Equity Research

Here's Why You Should Hold NextGen (NXGN) Stock For Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.

Zacks Equity Research

Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario

by Zacks Equity Research

Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.

Zacks Equity Research

Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm

by Zacks Equity Research

WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.